Clinical Trials Directory

Trials / Completed

CompletedNCT06876181

In Vivo Study of Local Tranexamic Acid Concentrations Following Intra-Articular Administration in Total Knee Arthroplasty

Status
Completed
Phase
Study type
Observational
Enrollment
48 (actual)
Sponsor
Valdoltra Orthopedic Hospital · Academic / Other
Sex
All
Age
40 Years – 85 Years
Healthy volunteers
Not accepted

Summary

The goal of this observational study is to measure local tranexamic acid (TXA) concentrations following intra-articular administration in patients undergoing total knee arthroplasty. By evaluating its pharmacokinetic profile in the periarticular hematoma, the study will also assess the safety of topically administered TXA considering its cytotoxicity in healthy periarticular tissue. The main questions it aims to answer are: * How does TXA concentration in periarticular hematoma change over time following intra-articular administration after TKA? * Do local TXA concentrations after standard intra-articular dose of 2 g exceed the proposed cytotoxic levels, and for how long? Participants will: * Receive standard 2 g of TXA intra-articularly at the end of surgery as per the estabished hospital protocol * Undergo intra-articular hematoma fluid sampling via a drainage catheter at 0.5, 1.5, 3, 6, and 9 hours postoperatively

Conditions

Interventions

TypeNameDescription
OTHERPharmacokinetics of Intra-Articularly Administered TXA: Postoperative Concentration Dynamics in Periarticular HematomaAs part of the standard total knee arthroplasty procedure, participants receive a 2 g dose of tranexamic acid into the joint space after suturing the joint capsule. Before closing the joint capsule, a silicone drain is inserted into the joint space, through which periarticular hematoma samples are collected aseptically at 0.5, 1.5, 3, 6, and 9 hours post-application.

Timeline

Start date
2022-08-23
Primary completion
2023-03-06
Completion
2024-09-30
First posted
2025-03-14
Last updated
2025-03-14

Locations

1 site across 1 country: Slovenia

Source: ClinicalTrials.gov record NCT06876181. Inclusion in this directory is not an endorsement.